Tysabri and Progressive Multifocal Leukoencephalopathy: Legal Considerations for New York Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Risk: The Legacy of Informed Vigilance

The legacy of general health and science information has long provided a foundation for public understanding of medical treatments and their potential risks. Within this broad context, the dissemination of knowledge about pharmaceutical interventions has enabled patients and healthcare providers to make informed decisions. As this informational heritage evolved, it increasingly emphasized the importance of monitoring adverse effects associated with therapeutic agents, particularly those used in chronic disease management. This shift toward vigilance naturally extends to the domain of mass production, where the widespread administration of biologic therapies necessitates careful scrutiny of long-term outcomes. In this setting, the transition from general health awareness to specific occupational exposure concerns becomes salient. For individuals who have been prescribed Tysabri, a medication used in the treatment of certain autoimmune conditions, the risk of developing progressive multifocal leukoencephalopathy represents a critical safety consideration. This concern is particularly acute in contexts where exposure to the drug occurs over extended periods, raising questions about the timing of legal recourse. In New York, the statute of limitations for claims related to Tysabri-associated progressive multifocal leukoencephalopathy requires careful attention, as it governs the window within which affected individuals may seek legal remedy. Thus, the heritage of general health information now pivots to a focused examination of exposure risk and its legal implications.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information includes a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and Tysabri treatment creates a state of immune suppression that can allow JCV reactivation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first indication of the disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. In the FDA Adverse Event Reporting System (FAERS), the most frequently reported adverse events associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and depression (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms can overlap with those of multiple sclerosis, making early diagnosis of PML challenging. Laboratory confirmation of PML typically involves detection of JCV DNA in cerebrospinal fluid by polymerase chain reaction (PCR), as noted for herpes infections in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of PML Development in Tysabri Patients

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist, which blocks lymphocyte adhesion and migration into the central nervous system. This reduces immune surveillance in the brain, allowing JCV to reactivate and cause lytic infection of oligodendrocytes. The resulting demyelination leads to the characteristic white matter lesions of PML. The risk is highest in patients who are anti-JCV antibody positive, have received Tysabri for more than two years, or have previously used immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Statute of Limitations for Tysabri Claims in New York

For patients in New York who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a claim. In New York, the statute of limitations for personal injury actions is generally three years from the date of injury, but this can vary based on when the injury was discovered or should have been discovered. For medical malpractice or product liability claims related to Tysabri and PML, the timeline between exposure and documented harm is critical. PML can develop months to years after starting Tysabri, and symptoms may initially be subtle. The prescribing information notes that herpes infections have been reported from a few months to several years after starting treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and PML risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Adequacy of warnings is a key issue in potential litigation. The boxed warning clearly states that Tysabri increases PML risk and identifies risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, patients and healthcare providers must rely on the TOUCH program to ensure informed consent and monitoring. If a patient was not adequately informed of PML risk or if monitoring was insufficient, there may be grounds for a claim. Attorney-related considerations include the need to document the date of PML diagnosis, the duration of Tysabri treatment, and any prior immunosuppressant use. The statute of limitations clock may start from the date of diagnosis or from when the patient knew or should have known that PML was caused by Tysabri.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in New York?

In New York, the statute of limitations for personal injury actions is generally three years from the date of injury. However, for Tysabri-related PML claims, the clock may start from the date of diagnosis or from when the patient knew or should have known that PML was caused by Tysabri. It is crucial to consult an attorney promptly to ensure your claim is filed within the applicable time frame.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed in Tysabri patients?

Laboratory confirmation of PML typically involves detection of JCV DNA in cerebrospinal fluid by polymerase chain reaction (PCR) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical symptoms such as progressive neurological deficits may also prompt evaluation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.